Featured Research

from universities, journals, and other organizations

New agent may enhance effectiveness of radiotherapy

Date:
May 13, 2014
Source:
Manchester University
Summary:
The potential of a drug to improve the effectiveness of radiotherapy in stopping tumor growth has been demonstrated by scientists. There is increasing interest in using the body’s own immune system to attack tumor cells – a strategy that can be very effective without the side effects associated with conventional chemotherapy. Skin cancers, for instance, have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognizes foreign and potentially harmful material.

Scientists from The University of Manchester -- part of the Manchester Cancer Research Centre -- have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumor growth.

There is increasing interest in using the body's own immune system to attack tumor cells -- a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Skin cancers have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognizes foreign and potentially harmful material.

Previously, researchers in Manchester have shown that they can also stimulate the immune system into generating an immune response against non-skin cancers by injecting an agent similar to TLR7 into the blood.

In collaboration with AstraZeneca and Dainippon Sumitomo Pharma, the Manchester group have looked at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they investigated DSR-6434 on its own and in combination with radiotherapy and measured the effect on the primary tumor and the number of secondary tumors in the lungs.

Professor Ian Stratford, from Manchester Pharmacy School who, with Professor Tim Illidge, led the research published in the International Journal of Cancer, said: "We have already seen a strong immune system response from other immunotherapy agents in combination with radiation -- this new agent appears to be even more potent."

His team showed that administering DSR-6434 together with radiotherapy led to tumor shrinkage and increased long-term survival. They found that the combination treatment also reduced the occurrence of secondary lung tumors.

"It looks like there's good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumors. These results strongly suggest that this sort of combination therapy should be evaluated in clinical trials with cancer patients," added Professor Stratford.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Amy L. Adlard, Simon J. Dovedi, Brian A. Telfer, Erina Koga-Yamakawa, Charlotte Pollard, Jamie Honeychurch, Timothy M. Illidge, Masashi Murata, David T. Robinson, Philip J. Jewsbury, Robert W. Wilkinson, Ian J. Stratford. A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. International Journal of Cancer, 2014; DOI: 10.1002/ijc.28711

Cite This Page:

Manchester University. "New agent may enhance effectiveness of radiotherapy." ScienceDaily. ScienceDaily, 13 May 2014. <www.sciencedaily.com/releases/2014/05/140513092330.htm>.
Manchester University. (2014, May 13). New agent may enhance effectiveness of radiotherapy. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/05/140513092330.htm
Manchester University. "New agent may enhance effectiveness of radiotherapy." ScienceDaily. www.sciencedaily.com/releases/2014/05/140513092330.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins